Opiant Pharmaceuticals Inc
The OPNT stock trades on Nasdaq All Markets
Company Description
Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose. We are headquartered in Santa Monica, with additional offices in London, UK. We were founded in 2009. In 2013, Opiant developed the first FDA-approved, user-friendly nasal naloxone spray. In 2015 this product, NARCAN® Nasal Spray 4mg, became available in the United States and Canada through our licensee, Adapt Pharma (now a part of Emergent BioSolutions). Opiant is now focused on advancing its pipeline alongside receiving royalties from NARCAN® Nasal Spray.
Drug Pipeline
Source: Opiant Pharmaceuticals Inc - 20220925
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
NARCAN
Opioid Overdose
Reg/Com
OPNT002
Alcohol Use Disorder
Phase 1
OPNT003
Opioid Overdose
Phase 3
OPNT004
Cannabinoid Overdose
Preclinical
0 Comments on OPNT stock
Newest
Trialfinder
betaCompletedPharmacokinetic Evaluation of Intranasal Nalmefene
CompletedPharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens
RecruitingPharmacodynamic Evaluation of Intranasal Nalmefene
Conversation